First pharma company joins IMPRESS-Norway
Roche contributes eight cancer medicines to IMPRESS-Norway.
From pupil to full-time employee
Our school collaboration project has opened unexpected doors for Eivind.
New political paper: Action Plan for Clinical Studies
Norwegian government to double the number of clinical studies.
Dehns acquires Norwegian office
Dehns acquires Norwegian Intellectual Property consultancy Leogriff.
New clinical study in ovarian cancer
Ultimovacs has announced a new clinical study targeted at patients with ovarian cancer.
Landmark public-private agreement for precision cancer medicine
CONNECT is a completely new public-private collaboration in cancer precision medicine.
